Risk of Medullary Thyroid Cancer with Mounjaro (Tirzepatide)

Clinical Evidence and Guidelines

• The American Diabetes Association recommends that GLP-1 receptor agonists, including tirzepatide, should not be used in patients with a personal or family history of medullary thyroid cancer or MEN 2 syndrome, as stated by the Diabetes Care guideline 3
• For patients with type 2 diabetes and obesity without MTC/MEN 2 history, tirzepatide offers significant glycemic control and weight loss benefits, with HbA1c reductions of 1.87-2.59% and weight loss of 20.9% at 72 weeks with the 15mg dose, according to Praxis Medical Insights 1
• The proven benefits of tirzepatide for glycemic control, weight reduction, and cardiometabolic health substantially outweigh the theoretical and unproven thyroid cancer risk, as supported by Praxis Medical Insights 2

Contraindications and Precautions

• The American College of Endocrinology and the European Association for the Study of Diabetes suggest that GLP-1 receptor agonists, including tirzepatide, are contraindicated in patients with a personal or family history of medullary thyroid cancer or MEN 2 syndrome, as reported in Diabetes Care 4